Exodus 2, Recombinant, Human (SLC, Secondary Lymphoid-tissue Chemokine, 6Ckine, TCA4)

SLC/CCL21, normally expressed in high endothelial venules and in T cell zones of spleen and lymph nodes, strongly attracts T cells and dendritic cells (DC). Secondary lymphoid tissue chemokine (CCL21/SLC) regulates the homing of naive T cells and dendritic cells that express CC-chemokine receptor 7 (CCR7) from distant sites to lymphoid tissue such as lymph nodes.\n\nDescription: \nRecombinant Human Exodus-2 is also known as SLC (Secondary Lymphoid-Tissue Chemokine), TCA-4 (T-cell activation-4) , and 6Ckine. Recombinant CCL21 produced in E.Coli as a single, non-glycosylated, polypeptide chain containing 111 amino acids and having a molecular mass of 12219 Dalton. Recombinant CCL-21 is purified by proprietary chromatographic techniques.\n\nAmino Acid Sequence: \nThe sequence of the first five N-terminal amino acids was determined and was found to be, Ser-Asp-Gly-Gly-Ala.\n\nDimers and Aggregates: \nLess than 1% as determined by silver-stained SDS-PAGE gel analysis.\n\nBiological Activity: \nRecombinant Human Exodus-2 is fully biologically active when compared to standard. The activity is determined by the chemoattract of human PBE (peripheral blood eosinophils) at a concentration between 0.1-10ng/ml.\n\nEndotoxin: \n(same/less than) 0.1ng/ug (IEU/ug) of Exodus-2.\n\nProtein Content: \nProtein quantitation was carried out by two independent methods:\n1. UV spectroscopy at 280 nm.\n2. Analysis by RP-HPLC, using a calibrated solution of Exodus-2 as a Reference Standard.\n\nSolubility: \nIt is recommended to reconstitute the lyophilized Exodus-2 in sterile 18MOmega-cm H2O not less than 100microg/ml, which can then be further diluted to other aqueous solutions.\n\nStability: \nLyophilized Exodus-2 although stable at room temperature for 3 weeks, should be stored desiccated below -180C. Upon reconstitution Exodus-2 should be stored at 40C between 2-7 days and for future use below -180C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

E9005-08H

Size

5ug

Form

Supplied as a lyophilized powder without additives.

Purity

(same/more than) 98% as determined by RP-HPLC, anion-exchange FPLC and/or reducing and non-reducing SDS-PAGE Silver Stained gel.

References

1. Role of CCL21 and CCL19 in allergic inflammation in the ovalbumin-specific murine asthmatic model. J Allergy Clin Immunol 2006 May;117(5):1040-6. 2. Loss of dendritic cell migration and impaired resistance to Leishmania donovani infection in mice deficient in CCL19 and CCL21. J Immunol 2006 May 1;176(9):5486-93. 3. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 2006 Mar 15;66(6):3205-13. 4. Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells. Cancer Sci 2005 Dec;96(12):889-96. 5. Role of CXC chemokine ligand 13, CC chemokine ligand (CCL) 19, and CCL21 in the organization and function of nasal-associated lymphoid tissue. J Immunol 2005 Oct 15;175(8):4904-13. 6. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Mol Ther 2006 Jan;13(1):194-202.